These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Efficacy and safety of thymoglobulin and basiliximab in kidney transplant patients at high risk for acute rejection and delayed graft function. Chen G; Gu J; Qiu J; Wang C; Fei J; Deng S; Li J; Huang G; Fu Q; Chen L Exp Clin Transplant; 2013 Aug; 11(4):310-4. PubMed ID: 23121641 [TBL] [Abstract][Full Text] [Related]
6. Induction with basiliximab plus thymoglobulin is effective and safe in old-for-old renal transplantation: six-month results of a prospective clinical study. Favi E; Gargiulo A; Spagnoletti G; Salerno MP; Silvestrini N; Valente I; Citterio F Transplant Proc; 2010 May; 42(4):1114-7. PubMed ID: 20534237 [TBL] [Abstract][Full Text] [Related]
7. Improved efficacy of basiliximab over antilymphocyte globulin induction therapy in paediatric renal transplantation. Clark G; Walsh G; Deshpande P; Koffman G Nephrol Dial Transplant; 2002 Jul; 17(7):1304-9. PubMed ID: 12105256 [TBL] [Abstract][Full Text] [Related]
8. Thymoglobulin Versus Basiliximab Induction Therapy in Low-Risk Kidney Transplant Recipients: A Single-Center Experience. Lee H; Lee S; Jeon JS; Kwon SH; Noh H; Han DC; Yun S; Song D Transplant Proc; 2018 Jun; 50(5):1285-1288. PubMed ID: 29880348 [TBL] [Abstract][Full Text] [Related]
9. The selective use of basiliximab versus thymoglobulin in combination with sirolimus for cadaveric renal transplant recipients at low risk versus high risk for delayed graft function. Knight RJ; Kerman RH; Schoenberg L; Podder H; Van Buren CT; Katz S; Kahan BD Transplantation; 2004 Sep; 78(6):904-10. PubMed ID: 15385812 [TBL] [Abstract][Full Text] [Related]
10. Basiliximab versus daclizumab combined with triple immunosuppression in deceased donor renal graft recipients. Grego K; Arnol M; Bren AF; Kmetec A; Tomaziĉ J; Kandus A Transplant Proc; 2007 Dec; 39(10):3093-7. PubMed ID: 18089329 [TBL] [Abstract][Full Text] [Related]
11. Renal allografts from donors older than 70 years are useful for single transplantation. Gavela E; Pallardó LM; Avila A; Sancho A; Beltrán S; Kanter J; Crespo JF Transplant Proc; 2009; 41(6):2047-9. PubMed ID: 19715828 [TBL] [Abstract][Full Text] [Related]
12. Rabbit antithymocyte globulin versus basiliximab in renal transplantation. Brennan DC; Daller JA; Lake KD; Cibrik D; Del Castillo D; N Engl J Med; 2006 Nov; 355(19):1967-77. PubMed ID: 17093248 [TBL] [Abstract][Full Text] [Related]
13. Comparison of single bolus ATG and Basiliximab as induction therapy in presensitized renal allograft recipients receiving tacrolimus-based immunosuppressive regimen. Yang SL; Wang D; Wu WZ; Lin WH; Xu TZ; Cai JQ; Tan JM Transpl Immunol; 2008 Jan; 18(3):281-5. PubMed ID: 18047938 [TBL] [Abstract][Full Text] [Related]
14. Immunoprophylaxis with basiliximab compared with antithymocyte globulin in renal transplant patients receiving MMF-containing triple therapy. Lebranchu Y; Bridoux F; Büchler M; Le Meur Y; Etienne I; Toupance O; Hurault de Ligny B; Touchard G; Moulin B; Le Pogamp P; Reigneau O; Guignard M; Rifle G Am J Transplant; 2002 Jan; 2(1):48-56. PubMed ID: 12095056 [TBL] [Abstract][Full Text] [Related]
15. Calcineurin inhibitor-free immunosuppressive strategy in elderly recipients of renal allografts from deceased donors: 1-year results from a prospective single center trial. Arbogast HP; Hoffmann JN; Illner WD; Hillebrand GF; Fischereder M; Jauch KW; Land W Transplant Proc; 2009; 41(6):2529-32. PubMed ID: 19715968 [TBL] [Abstract][Full Text] [Related]
16. Comparison of four different immunosuppression protocols without long-term steroid therapy in kidney recipients monitored by surveillance biopsy: five-year outcomes. Anil Kumar MS; Irfan Saeed M; Ranganna K; Malat G; Sustento-Reodica N; Kumar AM; Meyers WC Transpl Immunol; 2008 Nov; 20(1-2):32-42. PubMed ID: 18773960 [TBL] [Abstract][Full Text] [Related]
17. Thymoglobulin versus basiliximab induction therapy for simultaneous kidney-pancreas transplantation: impact on rejection, graft function, and long-term outcome. Bazerbachi F; Selzner M; Boehnert MU; Marquez MA; Norgate A; McGilvray ID; Schiff J; Cattral MS Transplantation; 2011 Nov; 92(9):1039-43. PubMed ID: 22002345 [TBL] [Abstract][Full Text] [Related]
18. Comparative study of the cellular pharmacodynamics of tacrolimus in renal transplant recipients treated with and without basiliximab. Sugiyama K; Isogai K; Horisawa S; Toyama A; Satoh H; Saito K; Nakagawa Y; Tasaki M; Takahashi K; Hirano T Cell Transplant; 2012; 21(2-3):565-70. PubMed ID: 22793066 [TBL] [Abstract][Full Text] [Related]
19. Basiliximab (Simulect) in renal transplantation with high risk for delayed graft function. Fernandez Rivera C; Alonso Hernandez A; Villaverde Verdejo P; Oliver García J; Valdés Cañedo F Transplant Proc; 2005 Apr; 37(3):1435-7. PubMed ID: 15866629 [TBL] [Abstract][Full Text] [Related]
20. Induction with basiliximab in renal transplantation. Ferrer F; Machado S; Alves R; Macário F; Bastos C; Roseiro A; Mota A Transplant Proc; 2010 Mar; 42(2):467-70. PubMed ID: 20304166 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]